Clinical trial
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated…
NCT00044187 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00044187 |
|---|---|
| Title | The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder |
| Official title | The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Psychotic Disorders, Bipolar Disorder |
| Intervention type | Drug |
| Interventions | Sibutramine |
| Enrollment | 130 |
| Start date | Apr 1, 2001 |
| Completion | Sep 1, 2003 |
| First posted | Aug 23, 2002 |
| Last update posted | Jul 19, 2006 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: